Back to top

LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy

LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

LivaNova PLC (LIVN)